Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02413827 |
| Title | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Celldex Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| California Pacific Medical Center Research Institute | San Francisco | California | 94115 | United States | Details | |
| Sutter Pacific Medical Foundation | Santa Rosa | California | 95403 | United States | Details | |
| University of Colorado | Aurora | Colorado | 80045 | United States | Details | |
| Georgetown University School of Medicine | Washington DC | District of Columbia | 20007 | United States | Details | |
| University of Chicago | Chicago | Illinois | 60637 | United States | Details | |
| Washington University School of Medicine | St. Louis | Missouri | 63110 | United States | Details | |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
| Tennessee Oncology Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States | Details |